ADARx Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 2 trials

TrialDrugs studiedStatusPrimary completion
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)NCT07428499ADX-324 Dose Level 1, ADX-324 Dose Level 2Recruiting2030-06-30Estimated
STOP-HAE: A Phase 3 Study of ADX-324 in HAENCT06960213ADX-324Recruiting2027-11-30Estimated

Phase 2 3 trials

TrialDrugs studiedStatusPrimary completion
Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseNCT06989359ADX-038 Dose Level 1, ADX-038 Dose Level 2, ADX-038 Dose Level 3Recruiting2030-04-30Estimated
Phase 2 Study of ADX-038 in Participants With Geographic AtrophyNCT06990269ADX-038Recruiting2030-02-28Estimated
Chinese Adults With Kidney DiseaseNCT07522099ADX-038, TelitaciceptRecruiting2028-07-10Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359 · ADARx Pharmaceuticals, Inc.

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Evaluate the safety and tolerability of ADX-038 Description: Incidence and severity of TEAEs Time frame: Length of study - 36 months. After: Measure: Evaluate the safety and tolerability of ADX-038 Description: Incidence and severity of TEAEs Time frame: Length of study - From Day 1 through Month 24.

Planned enrollment increased by 40 participants

Before: 45 participants (planned). After: 85 participants (planned).

Primary completion date changed

Before: 31 Dec 2028. After: 30 Apr 2030.

Check registry source
STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213 · ADARx Pharmaceuticals, Inc.

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Efficacy of ADX-324 in preventing investigator-confirmed HAE attacks. After: Measure: Efficacy of ADX-324 in preventing HAE attacks.

Primary completion date changed

Before: 31 Dec 2026. After: 30 Jun 2027.

Check registry source